Dr. Muhamad Alhaj Moustafa, M.D.
What this data tells you about Dr. Alhaj Moustafa
Dr. Muhamad Alhaj Moustafa is a hematology & oncology in Jacksonville, FL, with 11 years in practice. Based on federal Medicare data, Dr. Alhaj Moustafa performed 83,601 Medicare services across 2,636 unique beneficiaries.
Between the years covered by Open Payments, Dr. Alhaj Moustafa received a total of $13,942 from 28 pharmaceutical and/or device companies across 77 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Alhaj Moustafa is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 13,202 | $39 | $187 |
| Filgrastim injection (Nivestym) for white blood cells | 10,800 | $0 | $1 |
| Anti-nausea injection (fosaprepitant) | 9,150 | $0 | $1 |
| Nivolumab injection (Opdivo) | 8,960 | $21 | $102 |
| Daratumumab injection (Darzalex) | 5,760 | $38 | $190 |
| Iron infusion (Feraheme) | 5,610 | $0 | $2 |
| Paclitaxel chemotherapy injection | 4,836 | $0 | $2 |
| Darbepoetin injection (Aranesp) for anemia | 4,070 | $2 | $11 |
| Denosumab injection (Prolia/Xgeva) | 2,700 | $19 | $91 |
| Injection, paclitaxel protein-bound particles, 1 mg | 2,600 | $10 | $51 |
| Dexamethasone injection (steroid) | 1,888 | $0 | $4 |
| Injection, carfilzomib, 1 mg | 1,700 | $36 | $174 |
| Immune globulin infusion (Gammagard) | 1,550 | $34 | $138 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1,510 | $21 | $182 |
| Anti-nausea injection (ondansetron/Zofran) | 1,500 | $0 | $5 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,480 | $23 | $194 |
| Injection, atropine sulfate, 0.01 mg | 745 | $0 | $1 |
| Injection of additional new drug or substance into vein | 527 | $12 | $216 |
| Injection, bortezomib, 0.1 mg | 525 | $4 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 440 | $1 | $8 |
| Administration of chemotherapy into vein, 1 hour or less | 340 | $98 | $869 |
| Injection, irinotecan, 20 mg | 257 | $2 | $24 |
| Injection, carboplatin, 50 mg | 252 | $2 | $30 |
| Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 252 | $91 | $454 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 188 | $3 | $34 |
| Office visit, established patient (30-39 min) | 185 | $90 | $450 |
| Collection of blood sample from implanted device | 176 | $19 | $135 |
| Injection, fluorouracil, 500 mg | 168 | $2 | $31 |
| Infusion, normal saline solution , 1000 cc | 131 | $2 | $82 |
| Drug injection, under skin or into muscle | 125 | $11 | $102 |
| Injection, magnesium sulfate, per 500 mg | 120 | $1 | $19 |
| Injection, leucovorin calcium, per 50 mg | 118 | $3 | $23 |
| Infusion into a vein for hydration, each additional hour | 115 | $10 | $114 |
| Cyclophosphamide, 100 mg | 115 | $16 | $118 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 106 | $133 | $492 |
| Office visit, established patient, complex (40-54 min) | 104 | $137 | $604 |
| Administration of chemotherapy into vein, each additional hour | 101 | $22 | $212 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 100 | $22 | $233 |
| Administration of additional new drug or substance into vein, 1 hour or less | 99 | $48 | $446 |
| Hospital follow-up visit, high complexity | 93 | $96 | $452 |
| Injection, diphenhydramine hcl, up to 50 mg | 92 | $1 | $38 |
| Injection, cisplatin, powder or solution, 10 mg | 91 | $2 | $35 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 74 | $47 | $426 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 70 | $55 | $352 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 64 | $16 | $154 |
| Infusion into a vein for hydration, 31-60 minutes | 61 | $25 | $345 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 61 | $26 | $200 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 61 | $26 | $123 |
| Injection, zoledronic acid, 1 mg | 57 | $7 | $47 |
| Hospital follow-up visit, moderate complexity | 55 | $64 | $314 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 51 | $1 | $79 |
| New patient office visit, complex (60-74 min) | 39 | $159 | $891 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 30 | $15 | $143 |
| Administration of additional new drug or substance into vein using push technique | 26 | $43 | $370 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 24 | $133 | $993 |
| Initial hospital admission, high complexity | 19 | $140 | $877 |
| Hospital discharge management, 30+ min | 15 | $92 | $487 |
| Injection of drug or substance into vein | 13 | $29 | $600 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (51%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Alhaj Moustafa is a mixed practice specialist, with above-average Medicare volume (top 9% in FL), and consulting-driven industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Alhaj Moustafa experienced with pembrolizumab injection (keytruda)?
Does Dr. Alhaj Moustafa receive payments from pharmaceutical companies?
How do Dr. Alhaj Moustafa's costs compare to other hematology & oncologys in Jacksonville?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology